Please wait while the formulary information is being retrieved.
OPDUALAG (nivolumab-relatlimab-rmbw)
- metastatic malignant melanoma
240 mg-80 mg/20 mL intravenous solution
- Infuse 40 milliliters over 30 minute(s) by intravenous route every 4 weeks
Default screening record
- Infuse 40 milliliters over 30 minute(s) by intravenous route every 4 weeks
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactation
Contraindicated
- Adrenocortical insufficiency
- Colitis
- Hepatitis
- Hyperthyroidism
- Hypophysitis
- Hypothyroidism
- Interstitial pneumonitis
- Kidney disease with reduction in GFR
- Myocarditis
- Nephritis
- Pregnancy
Severe
Moderate
- Type 1 diabetes mellitus
OPDUALAG (nivolumab-relatlimab-rmbw)
- metastatic malignant melanoma
- Colitis
- Hypothyroidism
- Increased alanine transaminase
- Increased aspartate transaminase
- Lymphopenia
- Anorexia
- Cough
- Diarrhea
- Fatigue
- Headache disorder
- Hyponatremia
- Musculoskeletal pain
- Nausea
- Pruritus of skin
- Skin rash
More Frequent
Severe
Less Severe
- Adrenocortical insufficiency
- Autoimmune hepatitis
- Demyelination
- Hyperthyroidism
- Interstitial pneumonitis
- Kidney disease with reduction in GFR
- Myocarditis
- Pneumonia
- Thyroiditis
- Arthralgia
- Back pain
- Chills
- Dizziness
- Fever
- Flushing
- Hyperglycemia
- Peripheral sensory neuropathy
- Skin inflammation
- Vitiligo
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anemia
- Aplastic anemia
- Autoimmune hemolytic anemia
- Cytomegalovirus disease
- Diabetes mellitus
- Duodenitis
- Eaton-lambert syndrome
- Encephalitis
- Exfoliative dermatitis
- Graft-versus-host disease
- Guillain-barre syndrome
- Hemophagocytic lymphohistiocytosis
- Histiocytic necrotizing lymphadenitis
- Hyperbilirubinemia
- Hypersensitivity drug reaction
- Hypophysitis
- Interstitial nephritis
- Myelitis
- Myositis
- Pancreatitis
- Pericarditis
- Pituitary insufficiency
- Polymyalgia rheumatica
- Renal failure
- Rhabdomyolysis
- Sarcoidosis
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
- Uveitis
- Vasculitis
- Vogt-koyanagi-harada disease
Less Severe
- Arthritis
- Elevated serum amylase
- Elevated serum lipase
- Gastritis
- General weakness
- Muscle weakness
- Nephritis
- Peripheral motor neuropathy
- Peripheral neuritis
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Nivolumab-Relatlimab
Safety and effectiveness not established in age < 12 years.
- 1 Day – 12 Years
- Safety and effectiveness not established in age < 12 years.
Nivolumab And Relatlimab-rmbw
- Severity Level:
D
- Additional Notes: Theoretical risk based on moa; weigh maternal benefits vs poten. risks to fetus
Contraindicated
Nivolumab And Relatlimab-rmbw
Insufficient human data avail; potential for serious adverse effects
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data avail; potential for serious adverse effects |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Metastatic malignant melanoma | |
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
| 0-9 | A-Z |
|---|---|
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
Formulary Reference Tool